Stifel notes that the firm’s model is under review after Rapt Therapeutics (RAPT) disclosed this morning that they will discontinue development of RPT193, or zelnecirnon, after recent FDA feedback ...
According to Stifel analysts, Goliath Resources (TSX-V: GOT; OTCQB: GOTRF; WKN: A2P063) has provided further evidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results